StockData

Exozymes Inc. (EXOZ) stock

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.38−0.05 (-1.46%)

Close on Nov 19, 2026Market cap $31.37MP/E –Yield –

Exozymes free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Exozymes's free cash flow for the twelve months ending Sep 30, 2026 was -$7.80M. For fiscal 2025 it was -$6.67M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.67M–
FY2024Dec 31, 2024-$8.90M–
FY2023Dec 31, 2023-$1.47M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.53M–
Q2 FY2026Jun 30, 2026-$1.64M–
Q1 FY2026Mar 31, 2026-$1.58M–
Q4 FY2025Dec 31, 2025-$2.05M–
Q3 FY2025Sep 30, 2025-$1.87M–
Q2 FY2025Jun 30, 2025-$1.59M–
Q1 FY2025Mar 31, 2025-$1.16M-979.7%
Q4 FY2024Dec 31, 2024-$5.92M–
Q3 FY2024Sep 30, 2024-$541.52K–
Q2 FY2024Jun 30, 2024-$2.58M–
Q1 FY2024Mar 31, 2024$132.39K–
Q4 FY2023Dec 31, 2023-$893.02K–

More Exozymes figures

See a number that looks wrong?